CUMBERLAND PHARMACEUTICALS INC 8-K

What Happened
Cumberland Pharmaceuticals Inc. announced and filed an 8‑K on May 5, 2026 reporting its financial results for the three months ended March 31, 2026 (Q1 2026). The company issued a press release providing a company update and the quarterly financial results; that press release is attached to the Current Report as Exhibit 99.1 and is incorporated by reference. The filing is signed by John Hamm, Chief Financial Officer, dated May 5, 2026.

Key Details

• Press release dated May 5, 2026 announcing company update and Q1 2026 financial results.
• Results cover the three months ended March 31, 2026 (Q1 2026).
• Press release is attached as Exhibit 99.1 to the Form 8‑K and incorporated by reference.
• Form 8‑K was signed by CFO John Hamm on May 5, 2026.

Why It Matters
This Form 8‑K is the company’s timely public disclosure of its quarterly results and business update. Retail investors should review the attached press release (Exhibit 99.1) for the actual earnings, revenue, and other financial metrics and any commentary on operations or outlook. For full details, check the Exhibit 99.1 press release on the SEC EDGAR site or Cumberland’s investor relations page.